#scleroderma Suchergebnisse

Congratulations to Dr. Zsuzsanna McMahan on her award from Promote Altruism! This is supporting her critical work in the field of the debilitating GI manifestations of #scleroderma . Thank you for all you do for your patients! #rheumatology

UTHealthRheum's tweet image. Congratulations to Dr. Zsuzsanna McMahan on her award from Promote Altruism! This is supporting her critical work in the field of the debilitating GI manifestations of #scleroderma . Thank you for all you do for your patients! #rheumatology

✨How can we better understand and treat fibrotic diseases? Meet Dr. Dinesh Khanna at #ECM2026. @sclerodermaUM He is a Professor of Medicine and Director of the University of Michigan (@UMich) Scleroderma Program , pioneering precision research in #scleroderma and #fibrosis.

ecmcongress's tweet image. ✨How can we better understand and treat fibrotic diseases? 

Meet Dr. Dinesh Khanna at #ECM2026. @sclerodermaUM 

He is a Professor of Medicine and Director of the University of Michigan (@UMich) Scleroderma Program , pioneering precision research in #scleroderma and #fibrosis.

Excited to present WIN #scleroderma #eular2025. This slide highlights the opportunities in drug development in SSc. Come and join on Saturday 6/14 at 9 AM CET.

sclerodermaUM's tweet image. Excited to present  WIN  #scleroderma #eular2025. This slide highlights the opportunities in drug development in  SSc. Come and join on Saturday 6/14 at 9 AM CET.

Biologic Therapy for Refractory Juvenile Scleroderma” by Dr. Munirah Al Marri was accepted at #ACR25 – Chicago 🇺🇸! The world’s main rheumatology conference, covering both adult & pediatric advances. A proud step forward in improving care for young patients. #Scleroderma

Drasiri1000's tweet image. Biologic Therapy for Refractory Juvenile Scleroderma” by Dr. Munirah Al Marri
was accepted at #ACR25 – Chicago 🇺🇸!

The world’s main rheumatology conference, covering both adult & pediatric advances.
A proud step forward in improving care for young patients. 

#Scleroderma…

#scleroderma 1. why is SSc- a 'fibrotic disease' treated with immunosuppressive? 2. Why dont every patient with early SSc respond to immunosuppressive? the lessons lie in understanding the underlying mechanisms of early SSc and molecular heterogeneity. @IRACON24Blr

sclerodermaUM's tweet image. #scleroderma 
1. why is SSc- a 'fibrotic disease' treated with immunosuppressive?
2. Why dont every patient with early SSc respond to immunosuppressive? 
the lessons lie in understanding the underlying mechanisms of early SSc and molecular heterogeneity.  @IRACON24Blr
sclerodermaUM's tweet image. #scleroderma 
1. why is SSc- a 'fibrotic disease' treated with immunosuppressive?
2. Why dont every patient with early SSc respond to immunosuppressive? 
the lessons lie in understanding the underlying mechanisms of early SSc and molecular heterogeneity.  @IRACON24Blr

🏆 Meet the 2025 Major & Starting Grant winners from @WSF_Scleroderma! 👏 Their work drives research & hope for the #Scleroderma community. 🎧 Listen to Voices from SSc – Ep.1 🔗 Register free: worldsclerofound.org/register/ #WSFAcademy #SSc #Research #ILD

Worldsclerofnd's tweet image. 🏆 Meet the 2025 Major & Starting Grant winners from @WSF_Scleroderma!
👏 Their work drives research & hope for the #Scleroderma community.
🎧 Listen to Voices from SSc – Ep.1
🔗 Register free: worldsclerofound.org/register/
#WSFAcademy #SSc #Research #ILD
Worldsclerofnd's tweet image. 🏆 Meet the 2025 Major & Starting Grant winners from @WSF_Scleroderma!
👏 Their work drives research & hope for the #Scleroderma community.
🎧 Listen to Voices from SSc – Ep.1
🔗 Register free: worldsclerofound.org/register/
#WSFAcademy #SSc #Research #ILD

Excited to present data from RESET-SSc in #scleroderma #eular2025. CAR-T was well tolerated with beneficial effects on skin/ FVC. Exciting data on U-M IIS with LN bx showing complete depletion of B cells at 3 weeks and NFC showing normalization of capillary density and size

sclerodermaUM's tweet image. Excited to present data from RESET-SSc in #scleroderma #eular2025. CAR-T was well tolerated with beneficial effects on skin/ FVC. Exciting data on U-M IIS with LN bx showing complete depletion of B cells at 3 weeks and NFC showing normalization of capillary density and size
sclerodermaUM's tweet image. Excited to present data from RESET-SSc in #scleroderma #eular2025. CAR-T was well tolerated with beneficial effects on skin/ FVC. Exciting data on U-M IIS with LN bx showing complete depletion of B cells at 3 weeks and NFC showing normalization of capillary density and size
sclerodermaUM's tweet image. Excited to present data from RESET-SSc in #scleroderma #eular2025. CAR-T was well tolerated with beneficial effects on skin/ FVC. Exciting data on U-M IIS with LN bx showing complete depletion of B cells at 3 weeks and NFC showing normalization of capillary density and size
sclerodermaUM's tweet image. Excited to present data from RESET-SSc in #scleroderma #eular2025. CAR-T was well tolerated with beneficial effects on skin/ FVC. Exciting data on U-M IIS with LN bx showing complete depletion of B cells at 3 weeks and NFC showing normalization of capillary density and size

Hey everyone! Today is #WorldSclerodermaDay I’m raising awareness about this debilitating disease! I’m in my 4th year. Don’t give up hope! We will find a cure. I’m happy to be thriving. Thanks for the love! ❤️🙏🏼#scleroderma

ClaireDeVille3's tweet image. Hey everyone! Today is #WorldSclerodermaDay I’m raising awareness about this debilitating disease! I’m in my 4th year. Don’t give up hope! We will find a cure. I’m happy to be thriving. Thanks for the love! ❤️🙏🏼#scleroderma

#Scleroderma specific autoantibodies in predicting prognosis/survival ➡️ almost all #ANA positive 📈 Best survival in anticentromere group 📉 Diffuse subtype carries a worse prognosis especially Anti-Scl70, anti-RNA polymerase III & If 🫁 ILD present [AL Herrick]

LastManStand85's tweet image. #Scleroderma specific autoantibodies in predicting prognosis/survival 

➡️ almost all #ANA positive

📈 Best survival in anticentromere group
 
📉 Diffuse subtype carries a worse prognosis especially Anti-Scl70, anti-RNA polymerase III & If 🫁 ILD present 

[AL Herrick]

Exploring the intersection of #Scleroderma and #GAVE — uncovering key demographic and mortality trends from a national inpatient analysis. Honored to share our findings at #ACR2025! #RheumResearch

akanksha0411's tweet image. Exploring the intersection of #Scleroderma and #GAVE — uncovering key demographic and mortality trends from a national inpatient analysis. Honored to share our findings at #ACR2025! #RheumResearch

2 years ago,I was invited onto @BBCSheffield Paulette's show to talk about my #scleroderma I've kindly been invited back on to talk about allsorts this Wednesday morning! Wish me luck !!

sclerodermasara's tweet image. 2 years ago,I was invited onto @BBCSheffield Paulette's show to talk about my #scleroderma 
I've kindly been invited back on to talk about allsorts this Wednesday morning! Wish me luck !!

Systemic Sclerosis–Associated ILD Watch Alicia Hinze, MD, share personalized strategies for managing Systemic Sclerosis–Associated ILD. Sponsored By: Boehringer Ingelheim buff.ly/w9qmEr7 #ILD #Scleroderma

RheumNow's tweet image. Systemic Sclerosis–Associated ILD

Watch Alicia Hinze, MD, share personalized strategies for managing Systemic Sclerosis–Associated ILD. Sponsored By: Boehringer Ingelheim 

buff.ly/w9qmEr7 

#ILD #Scleroderma

👩‍⚕️ Tight, mask-like face? Think Scleroderma (Systemic Sclerosis) — not Sjögren’s or Lupus. Early recognition of skin tightening & Raynaud’s = better outcomes. #Rheumatology #MedTwitter #Scleroderma #GPs #RheumRounds @DrAkhilX @IhabFathiSulima @Janetbirdope

Rheumat_Aravind's tweet image. 👩‍⚕️ Tight, mask-like face?
Think Scleroderma (Systemic Sclerosis) — not Sjögren’s or Lupus.
Early recognition of skin tightening & Raynaud’s = better outcomes.

#Rheumatology #MedTwitter #Scleroderma #GPs #RheumRounds @DrAkhilX @IhabFathiSulima @Janetbirdope

This clinical sign is mostly associated with which of the following condition? A) Sjögren syndrome B) Scleroderma C) Dermatomyositis D) Lupus

TrackYourHeart's tweet image. This clinical sign is mostly associated with which of the following condition?
A) Sjögren syndrome
B) Scleroderma
C) Dermatomyositis
D) Lupus


🧵1/ 👁 Ever wanted to see autoimmune Microvascular dysfunction in action? Nailfold Videocapillaroscopy (NVC) gives us a live look into systemic vascular health. A powerful, non-invasive window for early diagnosis in CTDs. Let’s walk through what it reveals in #Scleroderma.…

IlliasulK's tweet image. 🧵1/
👁 Ever wanted to see autoimmune Microvascular dysfunction in action?

Nailfold Videocapillaroscopy (NVC) gives us a live look into systemic vascular health. A powerful, non-invasive window for early diagnosis in CTDs.

Let’s walk through what it reveals in #Scleroderma.…

Delighted to present the @bmsnews data on #scleroderma #eular2025. Breakfree-1 data showing CAR-T is well tolerated with beneficial effects on skin and FVC and composite endpoint, the revised CRISS.

sclerodermaUM's tweet image. Delighted to present the @bmsnews data on #scleroderma #eular2025. Breakfree-1 data showing CAR-T is well tolerated with beneficial effects on skin and FVC and composite endpoint, the revised CRISS.
sclerodermaUM's tweet image. Delighted to present the @bmsnews data on #scleroderma #eular2025. Breakfree-1 data showing CAR-T is well tolerated with beneficial effects on skin and FVC and composite endpoint, the revised CRISS.
sclerodermaUM's tweet image. Delighted to present the @bmsnews data on #scleroderma #eular2025. Breakfree-1 data showing CAR-T is well tolerated with beneficial effects on skin and FVC and composite endpoint, the revised CRISS.

World experts in #scleroderma Drs. Bottini and Assassi met up to moderate an excellent session at #ACR25 !

UTHealthRheum's tweet image. World experts in #scleroderma Drs. Bottini and Assassi met up to moderate an excellent session at #ACR25 !

Congratulations to Dr. Zsuzsanna McMahan on her award from Promote Altruism! This is supporting her critical work in the field of the debilitating GI manifestations of #scleroderma . Thank you for all you do for your patients! #rheumatology

UTHealthRheum's tweet image. Congratulations to Dr. Zsuzsanna McMahan on her award from Promote Altruism! This is supporting her critical work in the field of the debilitating GI manifestations of #scleroderma . Thank you for all you do for your patients! #rheumatology

``` 🚨 VEDOSS = EARLY #Scleroderma ✅ Must: Raynaud’s + ≥1 Red Flag 🔴 Puffy fingers → early swelling 🔴 +ve ANA (centromere/speckled) 🔴 Abnormal capillaroscopy 🔴 SSc antibodies (ACA, topo, RNA pol) ⚠️ ≥3 flags = 80–90% → SSc in 5 yrs Screen NOW! #scleroderma


✨How can we better understand and treat fibrotic diseases? Meet Dr. Dinesh Khanna at #ECM2026. @sclerodermaUM He is a Professor of Medicine and Director of the University of Michigan (@UMich) Scleroderma Program , pioneering precision research in #scleroderma and #fibrosis.

ecmcongress's tweet image. ✨How can we better understand and treat fibrotic diseases? 

Meet Dr. Dinesh Khanna at #ECM2026. @sclerodermaUM 

He is a Professor of Medicine and Director of the University of Michigan (@UMich) Scleroderma Program , pioneering precision research in #scleroderma and #fibrosis.

Primary Raynaud's is not correlated with any underlying medical condition, whereas secondary Raynaud's is causally connected to another medical condition, such as #scleroderma or #lupus. Read more, here: bit.ly/3bL8xkT #raynaudsphenomenon #frosties


#ACR25 Unlike other CTDs, #scleroderma -diagnosis a little bit later -few of patients (but not none) desire pregnancy this study show: Fetal and maternal outcomes in #systemicsclerosis pregnancies, are not big issue. This is promising for SSc acrabstracts.org/abstract/fetal…


🏆 Meet the 2025 Major & Starting Grant winners from @WSF_Scleroderma! 👏 Their work drives research & hope for the #Scleroderma community. 🎧 Listen to Voices from SSc – Ep.1 🔗 Register free: worldsclerofound.org/register/ #WSFAcademy #SSc #Research #ILD

Worldsclerofnd's tweet image. 🏆 Meet the 2025 Major & Starting Grant winners from @WSF_Scleroderma!
👏 Their work drives research & hope for the #Scleroderma community.
🎧 Listen to Voices from SSc – Ep.1
🔗 Register free: worldsclerofound.org/register/
#WSFAcademy #SSc #Research #ILD
Worldsclerofnd's tweet image. 🏆 Meet the 2025 Major & Starting Grant winners from @WSF_Scleroderma!
👏 Their work drives research & hope for the #Scleroderma community.
🎧 Listen to Voices from SSc – Ep.1
🔗 Register free: worldsclerofound.org/register/
#WSFAcademy #SSc #Research #ILD

Exploring the intersection of #Scleroderma and #GAVE — uncovering key demographic and mortality trends from a national inpatient analysis. Honored to share our findings at #ACR2025! #RheumResearch

akanksha0411's tweet image. Exploring the intersection of #Scleroderma and #GAVE — uncovering key demographic and mortality trends from a national inpatient analysis. Honored to share our findings at #ACR2025! #RheumResearch

UT Houston #Rheumatology division welcomes Dr. Jörg Distler who shared his incredible work regarding molecular profiling of fibroblasts in #scleroderma. Thank you for your insights and all of your efforts!

UTHealthRheum's tweet image. UT Houston #Rheumatology division welcomes Dr. Jörg Distler who shared his incredible work regarding molecular profiling of fibroblasts in #scleroderma. Thank you for your insights and all of your efforts!
UTHealthRheum's tweet image. UT Houston #Rheumatology division welcomes Dr. Jörg Distler who shared his incredible work regarding molecular profiling of fibroblasts in #scleroderma. Thank you for your insights and all of your efforts!

World experts in #scleroderma Drs. Bottini and Assassi met up to moderate an excellent session at #ACR25 !

UTHealthRheum's tweet image. World experts in #scleroderma Drs. Bottini and Assassi met up to moderate an excellent session at #ACR25 !

Primary Raynaud's is not correlated with any underlying medical condition, whereas secondary Raynaud's is causally connected to another medical condition, such as #scleroderma or #lupus. Read more, here: bit.ly/3bL8xkT #raynaudsphenomenon #frosties


#ACR25: Mary Alore, #Scleroderma patient and advocate, speaking Oct. 28 at the 2025 @ACRheum Convergence in Chicago about #CognitiveDysfunction or “brain fog” in #RheumaticDiseases. Image & quote taken by Senior Correspondent, @LLuxner #RareDisease #Rheumatology #BrainFog

RareDisease_Adv's tweet image. #ACR25:  Mary Alore, #Scleroderma patient and advocate, speaking Oct. 28 at the 2025 @ACRheum Convergence in Chicago about #CognitiveDysfunction or “brain fog” in #RheumaticDiseases.

Image & quote taken by Senior Correspondent, @LLuxner

#RareDisease #Rheumatology #BrainFog

Join us at clinical trial booth #972 at @ACRheum 2025 to learn more about the RESOLUTION trial, our investigational dual-targeted CD19/CD70 allogeneic CAR T for adults with #lupus, #myositis, and #scleroderma. $ALLO

AllogeneTx's tweet image. Join us at clinical trial booth #972 at @ACRheum 2025 to learn more about the RESOLUTION trial, our investigational dual-targeted CD19/CD70 allogeneic CAR T for adults with #lupus, #myositis, and #scleroderma. $ALLO

Excited to present WIN #scleroderma #eular2025. This slide highlights the opportunities in drug development in SSc. Come and join on Saturday 6/14 at 9 AM CET.

sclerodermaUM's tweet image. Excited to present  WIN  #scleroderma #eular2025. This slide highlights the opportunities in drug development in  SSc. Come and join on Saturday 6/14 at 9 AM CET.

Congratulations to Dr. Zsuzsanna McMahan on her award from Promote Altruism! This is supporting her critical work in the field of the debilitating GI manifestations of #scleroderma . Thank you for all you do for your patients! #rheumatology

UTHealthRheum's tweet image. Congratulations to Dr. Zsuzsanna McMahan on her award from Promote Altruism! This is supporting her critical work in the field of the debilitating GI manifestations of #scleroderma . Thank you for all you do for your patients! #rheumatology

🏆 Meet the 2025 Major & Starting Grant winners from @WSF_Scleroderma! 👏 Their work drives research & hope for the #Scleroderma community. 🎧 Listen to Voices from SSc – Ep.1 🔗 Register free: worldsclerofound.org/register/ #WSFAcademy #SSc #Research #ILD

Worldsclerofnd's tweet image. 🏆 Meet the 2025 Major & Starting Grant winners from @WSF_Scleroderma!
👏 Their work drives research & hope for the #Scleroderma community.
🎧 Listen to Voices from SSc – Ep.1
🔗 Register free: worldsclerofound.org/register/
#WSFAcademy #SSc #Research #ILD
Worldsclerofnd's tweet image. 🏆 Meet the 2025 Major & Starting Grant winners from @WSF_Scleroderma!
👏 Their work drives research & hope for the #Scleroderma community.
🎧 Listen to Voices from SSc – Ep.1
🔗 Register free: worldsclerofound.org/register/
#WSFAcademy #SSc #Research #ILD

Excited to present data from RESET-SSc in #scleroderma #eular2025. CAR-T was well tolerated with beneficial effects on skin/ FVC. Exciting data on U-M IIS with LN bx showing complete depletion of B cells at 3 weeks and NFC showing normalization of capillary density and size

sclerodermaUM's tweet image. Excited to present data from RESET-SSc in #scleroderma #eular2025. CAR-T was well tolerated with beneficial effects on skin/ FVC. Exciting data on U-M IIS with LN bx showing complete depletion of B cells at 3 weeks and NFC showing normalization of capillary density and size
sclerodermaUM's tweet image. Excited to present data from RESET-SSc in #scleroderma #eular2025. CAR-T was well tolerated with beneficial effects on skin/ FVC. Exciting data on U-M IIS with LN bx showing complete depletion of B cells at 3 weeks and NFC showing normalization of capillary density and size
sclerodermaUM's tweet image. Excited to present data from RESET-SSc in #scleroderma #eular2025. CAR-T was well tolerated with beneficial effects on skin/ FVC. Exciting data on U-M IIS with LN bx showing complete depletion of B cells at 3 weeks and NFC showing normalization of capillary density and size
sclerodermaUM's tweet image. Excited to present data from RESET-SSc in #scleroderma #eular2025. CAR-T was well tolerated with beneficial effects on skin/ FVC. Exciting data on U-M IIS with LN bx showing complete depletion of B cells at 3 weeks and NFC showing normalization of capillary density and size

#scleroderma 1. why is SSc- a 'fibrotic disease' treated with immunosuppressive? 2. Why dont every patient with early SSc respond to immunosuppressive? the lessons lie in understanding the underlying mechanisms of early SSc and molecular heterogeneity. @IRACON24Blr

sclerodermaUM's tweet image. #scleroderma 
1. why is SSc- a 'fibrotic disease' treated with immunosuppressive?
2. Why dont every patient with early SSc respond to immunosuppressive? 
the lessons lie in understanding the underlying mechanisms of early SSc and molecular heterogeneity.  @IRACON24Blr
sclerodermaUM's tweet image. #scleroderma 
1. why is SSc- a 'fibrotic disease' treated with immunosuppressive?
2. Why dont every patient with early SSc respond to immunosuppressive? 
the lessons lie in understanding the underlying mechanisms of early SSc and molecular heterogeneity.  @IRACON24Blr

Biologic Therapy for Refractory Juvenile Scleroderma” by Dr. Munirah Al Marri was accepted at #ACR25 – Chicago 🇺🇸! The world’s main rheumatology conference, covering both adult & pediatric advances. A proud step forward in improving care for young patients. #Scleroderma

Drasiri1000's tweet image. Biologic Therapy for Refractory Juvenile Scleroderma” by Dr. Munirah Al Marri
was accepted at #ACR25 – Chicago 🇺🇸!

The world’s main rheumatology conference, covering both adult & pediatric advances.
A proud step forward in improving care for young patients. 

#Scleroderma…

✨How can we better understand and treat fibrotic diseases? Meet Dr. Dinesh Khanna at #ECM2026. @sclerodermaUM He is a Professor of Medicine and Director of the University of Michigan (@UMich) Scleroderma Program , pioneering precision research in #scleroderma and #fibrosis.

ecmcongress's tweet image. ✨How can we better understand and treat fibrotic diseases? 

Meet Dr. Dinesh Khanna at #ECM2026. @sclerodermaUM 

He is a Professor of Medicine and Director of the University of Michigan (@UMich) Scleroderma Program , pioneering precision research in #scleroderma and #fibrosis.

#Calcinosis is tough to treat! Here’s a nice summary of options to consider in #Scleroderma & #DM including biologics (RTX in SSc and Tofacitinib in DM) and Minocycline 👉 Needs individualizing! Excellent talk by Dr. Valenzuela #ACR24 #ACRambassador #ReviewCourse @ACRheum

AshimaMakol's tweet image. #Calcinosis is tough to treat! 

Here’s a nice summary of options to consider in #Scleroderma & #DM including biologics (RTX in SSc and Tofacitinib in DM) and Minocycline
👉 Needs individualizing!

Excellent talk by Dr. Valenzuela 

#ACR24 #ACRambassador
#ReviewCourse
@ACRheum
AshimaMakol's tweet image. #Calcinosis is tough to treat! 

Here’s a nice summary of options to consider in #Scleroderma & #DM including biologics (RTX in SSc and Tofacitinib in DM) and Minocycline
👉 Needs individualizing!

Excellent talk by Dr. Valenzuela 

#ACR24 #ACRambassador
#ReviewCourse
@ACRheum

Dr. Aos Aboabat, #Scleroderma Clinical Research Fellow @SchroederInst, supervised by Dr. @SindhuJohnson5, presented his research at the Rheumatology Ogryzlo Research Day @UofT and will be graduating this year!  #WorldSclerodermaDay

SchroederInst's tweet image. Dr. Aos Aboabat, #Scleroderma Clinical Research Fellow @SchroederInst, supervised by Dr. @SindhuJohnson5, presented his research at the Rheumatology Ogryzlo Research Day @UofT and will be graduating this year!  #WorldSclerodermaDay
SchroederInst's tweet image. Dr. Aos Aboabat, #Scleroderma Clinical Research Fellow @SchroederInst, supervised by Dr. @SindhuJohnson5, presented his research at the Rheumatology Ogryzlo Research Day @UofT and will be graduating this year!  #WorldSclerodermaDay

Hey everyone! Today is #WorldSclerodermaDay I’m raising awareness about this debilitating disease! I’m in my 4th year. Don’t give up hope! We will find a cure. I’m happy to be thriving. Thanks for the love! ❤️🙏🏼#scleroderma

ClaireDeVille3's tweet image. Hey everyone! Today is #WorldSclerodermaDay I’m raising awareness about this debilitating disease! I’m in my 4th year. Don’t give up hope! We will find a cure. I’m happy to be thriving. Thanks for the love! ❤️🙏🏼#scleroderma

Great @SmidtHeart #research seminar by X. Mike Jones. Lead #ncRNA compound TY1 reverses the key manifestations of #scleroderma in two complementary mouse models! It even works orally. Next goal: first-in-human studies in #systemicsclerosis patients! @CedarsSinaiMed

MarbanLab's tweet image. Great @SmidtHeart #research seminar by X. Mike Jones. Lead #ncRNA compound TY1 reverses the key manifestations of #scleroderma in two complementary mouse models! It even works orally. Next goal: first-in-human studies in #systemicsclerosis patients!
@CedarsSinaiMed

#Scleroderma specific autoantibodies in predicting prognosis/survival ➡️ almost all #ANA positive 📈 Best survival in anticentromere group 📉 Diffuse subtype carries a worse prognosis especially Anti-Scl70, anti-RNA polymerase III & If 🫁 ILD present [AL Herrick]

LastManStand85's tweet image. #Scleroderma specific autoantibodies in predicting prognosis/survival 

➡️ almost all #ANA positive

📈 Best survival in anticentromere group
 
📉 Diffuse subtype carries a worse prognosis especially Anti-Scl70, anti-RNA polymerase III & If 🫁 ILD present 

[AL Herrick]

Bang-up @MarbanLab mtg presentation by @nih_nhlbi #T32 fellow @XMichaelJonesMD gives new hope for #scleroderma. In two #mouse models and human #SSc #macrophages (🙏@fboinMD), #ncRNA drug TY1 attenuates #DNAdamage and reverses disease. 👍. Thanks Mike for your great work!…

MarbanLab's tweet image. Bang-up @MarbanLab mtg presentation by @nih_nhlbi #T32 fellow @XMichaelJonesMD gives new hope for #scleroderma. In two #mouse models and human #SSc #macrophages (🙏@fboinMD), #ncRNA drug TY1 attenuates #DNAdamage and reverses disease. 👍. Thanks Mike for your great work!…
MarbanLab's tweet image. Bang-up @MarbanLab mtg presentation by @nih_nhlbi #T32 fellow @XMichaelJonesMD gives new hope for #scleroderma. In two #mouse models and human #SSc #macrophages (🙏@fboinMD), #ncRNA drug TY1 attenuates #DNAdamage and reverses disease. 👍. Thanks Mike for your great work!…
MarbanLab's tweet image. Bang-up @MarbanLab mtg presentation by @nih_nhlbi #T32 fellow @XMichaelJonesMD gives new hope for #scleroderma. In two #mouse models and human #SSc #macrophages (🙏@fboinMD), #ncRNA drug TY1 attenuates #DNAdamage and reverses disease. 👍. Thanks Mike for your great work!…
MarbanLab's tweet image. Bang-up @MarbanLab mtg presentation by @nih_nhlbi #T32 fellow @XMichaelJonesMD gives new hope for #scleroderma. In two #mouse models and human #SSc #macrophages (🙏@fboinMD), #ncRNA drug TY1 attenuates #DNAdamage and reverses disease. 👍. Thanks Mike for your great work!…

#Scleroderma mimics From Textbook Scleroderma From Pathogenesis to Comprehensive management. Chapter 11 (Hummers et Tyndall) 2024 👇 #Rheumatology #MedTwitter

LastManStand85's tweet image. #Scleroderma mimics 
From Textbook Scleroderma From Pathogenesis to Comprehensive management. Chapter 11 (Hummers et Tyndall) 2024 👇 
#Rheumatology #MedTwitter

#Scleroderma organ specific associated antibodies. #systemicsclerosis & Antibodies associated w/overlap SSc Extracted from Textbook Scleroderma From Pathogenesis to Comprehensive management 2024 #Rheumatology #MedTwitter 👇

LastManStand85's tweet image. #Scleroderma organ specific associated antibodies. #systemicsclerosis & Antibodies associated w/overlap SSc 

Extracted from Textbook Scleroderma From Pathogenesis to Comprehensive management 2024 

#Rheumatology #MedTwitter 

👇
LastManStand85's tweet image. #Scleroderma organ specific associated antibodies. #systemicsclerosis & Antibodies associated w/overlap SSc 

Extracted from Textbook Scleroderma From Pathogenesis to Comprehensive management 2024 

#Rheumatology #MedTwitter 

👇

🆕CD19 CAR T Cell treatment -A potentially promising future treatment in #SLE #scleroderma #myositis -Needs close collaboration with haematology Great explanation by @chriswincup #ACR24 #Lupus #SystemicSclerosis #IIM

gurdeep_dulay's tweet image. 🆕CD19 CAR T Cell treatment

-A potentially promising future treatment in #SLE #scleroderma #myositis 

-Needs close collaboration with haematology

Great explanation by @chriswincup #ACR24  #Lupus #SystemicSclerosis #IIM

Loading...

Something went wrong.


Something went wrong.


United States Trends